Shaukat Ali

Ascendia Pharmaceuticals Inc., USA

Title: Lipid Nanoparticles: Enabling technology for enhancing bioavailability of drugs

---

Biography

Dr. Ali has worked in the pharma industry about 30 years as innovator and formulator in design and development of oncology and small drug molecules. His area of expertise are synthesis, lipids and surfactants, oral, topical and parenteral formulations, liposomes drug delivery of small molecules and biologics. Dr. Ali obtained his PhD in chemistry from the City University of New York and caried out the postdoctoral training in physical biochemistry at the University of Minnesota and Cornell University, He returned to the industry and joined a pharma/ biotech after a brief tenure at the US university. He has published over 45 articles in scientific journals and inventor in 14 US patents. Dr. Ali is USP member of expert for the Excipient Test Methods committee and is the recipient of 2020 IPEC Foundation’s Henk de Jong industrial research award. 

Abstract

Lipid nanoparticles (LNPs) are extensively explored as alternative drug delivery systems for encapsulation and specific tissue targeting. With innovative lipids and surfactants, finding smarter lipids as nanocarriers for efficient encapsulation and delivery of small and large molecules, vaccines, plasmids DNA and mRNA are all within reach.   Thus, LNPs comprised of lipids and/or surfactants, and are used as liposomes, solid lipid nanoparticles (SLNs), and nanostructured lipid carriers (NLCs) for immediate and sustained release formulation of drugs for unmet needs. Ascendia’s proprietary solubilization technologies like Emulsol®, Amorsol®, and Nanosol®, are designed to meet the solubility challenges for immediate oral and long acting injectable suspensions of small molecules and biologics. 

This presentation will focus on our formulation technologies and their relevance in development of oral and injectable suspensions of innovative molecules and complex generics.